Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma

Int J Biol Markers. 2011 Apr-Jun;26(2):82-7. doi: 10.5301/JBM.2011.8344.


Cutaneous malignant melanoma (CMM) is the most serious type of skin cancer because of its tendency to metastasize. The prognosis and therapeutic management of patients are primarily based on clinical criteria (number of cancerous lymph nodes and/or the presence of distant metastases) and histopathological criteria (tumor depth, presence of ulceration and mitotic index). Although these factors are informative in advanced stages of the disease, they are less important in the early stages. In recent years, a number of attempts have been made to identify new serological prognostic biomarkers, especially for early forms of CMM. The recent development of proteomic techniques may offer new perspectives in this field. This article details the considerations of each of the proteomic techniques used today and describes the results of the most recent clinical studies conducted to identify new potential prognostic serum biomarkers for CMM. However, independent and large validation studies are needed before such markers can be used in everyday clinical practice.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / metabolism
  • Electrophoresis, Gel, Two-Dimensional / methods
  • Humans
  • Lymph Nodes / pathology
  • Melanoma / blood*
  • Melanoma / secondary
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Prognosis
  • Protein Array Analysis
  • Proteomics / methods*
  • Skin Neoplasms / blood*
  • Skin Neoplasms / pathology
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods


  • Biomarkers, Tumor